{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:57:01Z","timestamp":1774317421252,"version":"3.50.1"},"reference-count":52,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Polish Ministry of Science and Higher Education","doi-asserted-by":"publisher","award":["1\/2025"],"award-info":[{"award-number":["1\/2025"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Polish Ministry of Science and Higher Education","doi-asserted-by":"publisher","award":["8\/2025"],"award-info":[{"award-number":["8\/2025"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ceftobiprole is a novel and promising antibiotic; however, the direct pharmacological use of its native form is limited by its low water solubility. The first part of this study provides a deeper insight into the physicochemical properties of this drug. One- and two-dimensional nuclear magnetic resonance (NMR) spectra in D2O were recorded, and a complete assignment of 1H and 13C signals was achieved with the support of quantum mechanical calculations. The combined results from capillary electrophoresis and NMR confirmed the cationic nature of ceftobiprole at pH values well below 3 and the protonation of the secondary amino group, thus supporting the theoretically predicted dominant protonation states. Molecular dynamics simulations revealed that zwitterionic ceftobiprole molecules associate through hydrogen bonding, whereas in the cationic form, the attractive forces involve weaker \u03c0-\u03c0 and stacking interactions. The use of ceftobiprole in its native form in pharmaceutical formulations was made possible through the development of a novel freeze-dried cyclodextrin-based delivery system. Consequently, the second part of this article focuses on evaluating the biological properties of this system (ceftobiprole\/maleic acid\/sulfobutylether-\u03b2-cyclodextrin in a molar ratio of 1:25:4), including its antibacterial activity against the most common pneumonia-causing pathogens and its cytotoxicity towards normal and cancer cells.<\/jats:p>","DOI":"10.3390\/ijms262412108","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:41:12Z","timestamp":1765899672000},"page":"12108","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Physicochemical Characterisation of Ceftobiprole and Investigation of the Biological Properties of Its Cyclodextrin-Based Delivery System"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-7356","authenticated-orcid":false,"given":"Dariusz","family":"Boczar","sequence":"first","affiliation":[{"name":"Department of Synthetic Drugs, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-8656","authenticated-orcid":false,"given":"Wojciech","family":"Bocian","sequence":"additional","affiliation":[{"name":"Laboratory for Analysis of Bioactive Compounds, Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44\/52, 01-224 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2630-7731","authenticated-orcid":false,"given":"Krystian","family":"Ma\u0142ek","sequence":"additional","affiliation":[{"name":"Department of Biomedical Research, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1209-9477","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Milczarek","sequence":"additional","affiliation":[{"name":"Department of Biomedical Research, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5989-4462","authenticated-orcid":false,"given":"Agnieszka Ewa","family":"Laudy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Microbiology and Bioanalysis, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-3081","authenticated-orcid":false,"given":"Katarzyna","family":"Michalska","sequence":"additional","affiliation":[{"name":"Department of Synthetic Drugs, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lupia, T., Pallotto, C., Corcione, S., Boglione, L., and De Rosa, F.G. (2021). Ceftobiprole Perspective: Current and Potential Future Indications. Antibiotics, 10.","DOI":"10.3390\/antibiotics10020170"},{"key":"ref_2","unstructured":"Drug and Health Product Portal (Canada) (2025, December 01). Summary Basis of Decision for Zeftera. Available online: https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SBD00163."},{"key":"ref_3","unstructured":"U.S. Food and Drug Administration (2025, December 01). FDA Approves New Antibiotic for Three Different Uses, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-antibiotic-three-different-uses."},{"key":"ref_4","unstructured":"Medicines and Healthcare Products Regulatory Agency (United Kingdom) (2025, December 01). Public Assessment Report\u2014Zevtera 500 mg Powder for Concentrate for Solution for Infusion (UK\/H\/5304\/001\/DC), Available online: https:\/\/products.mhra.gov.uk\/search\/?search=zevtera."},{"key":"ref_5","unstructured":"Coordination Group for Mutual Recognition and Decentralised Procedures\u2014Human (CMDh) (2025, December 01). EU PSUR Work Sharing Summary Assessment Report. Available online: https:\/\/www.hma.eu\/fileadmin\/dateien\/Human_Medicines\/CMD_h_\/Pharmacovigilance_Legislation\/PSUR\/Outcome_of_informal_PSUR_WS_procedures\/Ceftobiprole_SmAR_09_2019.pdf."},{"key":"ref_6","unstructured":"European Medicines Agency (2025, December 01). List of Nationally Authorised Medicinal Products. Active Substance(s): Ceftobiprole. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/ceftobiprole-list-nationally-authorised-medicinal-products-psusa-00010734-202411_en.pdf."},{"key":"ref_7","unstructured":"European Medicines Agency (2025, December 01). Refusal of the Marketing Authorisation for Zeftera (Ceftobiprole). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_en.pdf."},{"key":"ref_8","unstructured":"European Medicines Agency (2025, December 01). Zeftera (Previously Zevtera). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zeftera."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Boczar, D., Bocian, W., Sitkowski, J., Pioru\u0144ska, K., and Michalska, K. (2025). Development of a Cyclodextrin-Based Drug Delivery System to Improve the Physicochemical Properties of Ceftobiprole as a Model Antibiotic. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26135953"},{"key":"ref_10","unstructured":"Angehrn, P. (1997). Vinyl Pyrrolidine Cephalosporins with Basic Substituents. (0849269 A1), EP."},{"key":"ref_11","unstructured":"Angehrn, P., Hebeisen, P., Heinze-Krauss, I., Page, M., and Runt, V. (1997). Vinyl-Pyrrolidinone Cephalosporins. (5981519A), US."},{"key":"ref_12","unstructured":"Ghetti, P., Hebeisen, P., Heubes, M., Pozzi, G., and Schleimer, M. (2010). New Crystal Polymorphs of Ceftobiprole. (2010072672A1), WO."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11364","DOI":"10.1039\/D1SC01185E","article-title":"Fitting quantum machine learning potentials to experimental free energy data: Predicting tautomer ratios in solution","volume":"12","author":"Wieder","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_14","unstructured":"(2025, December 01). DrugBank Online. Ceftobiprole: Uses, Interactions, Mechanism of Action. Available online: https:\/\/go.drugbank.com\/drugs\/DB04918."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Boczar, D., Bus, K., and Michalska, K. (2022). Study of Degradation Kinetics and Structural Analysis of Related Substances of Ceftobiprole by HPLC with UV and MS\/MS Detection. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232315252"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Boczar, D., and Michalska, K. (2023). Investigation of the Affinity of Ceftobiprole for Selected Cyclodextrins Using Molecular Dynamics Simulations and HPLC. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316644"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Boczar, D., and Michalska, K. (2022). Cyclodextrin Inclusion Complexes with Antibiotics and Antibacterial Agents as Drug-Delivery Systems-A Pharmaceutical Perspective. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071389"},{"key":"ref_18","unstructured":"Morrison, R.T., and Boyd, R.N. (1992). Organic Chemistry, Benjamin-Cummings Pub Co."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mart\u00edn, V., Col\u00f3n, A., Barrientos, C., and Le\u00f3n, I. (2025). Stabilization of Zwitterionic Versus Canonical Glycine by DMSO Molecules. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081168"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/elps.202400107","article-title":"Investigation of induced electroosmotic flow in small-scale capillary electrophoresis devices: Strategies for control and reversal","volume":"45","author":"Opallage","year":"2024","journal-title":"Electrophoresis"},{"key":"ref_21","unstructured":"Kremminger, P., Ludescher, J., and Sturm, H. (2010). Method for the Production of Ceftobiprole Medocaril. (20120108807 A1), US."},{"key":"ref_22","unstructured":"(2023, October 18). ChemAxon. Chemicalize. Available online: https:\/\/chemicalize.com\/welcome."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","article-title":"Epik: A software program for pKaprediction and protonation state generation for drug-like molecules","volume":"21","author":"Shelley","year":"2007","journal-title":"J. Comput.-Aided Mol. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23099","DOI":"10.1039\/D2RA03910A","article-title":"Oxazoline scaffold in synthesis of benzosiloxaboroles and related ring-expanded heterocycles: Diverse reactivity, structural peculiarities and antimicrobial activity","volume":"12","author":"Krajewska","year":"2022","journal-title":"RSC Adv."},{"key":"ref_25","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2025, December 01). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 15.0, Valid from 2025-01-01. Available online: https:\/\/www.eucast.org\/bacteria\/clinical-breakpoints-and-interpretation\/clinical-breakpoint-tables\/."},{"key":"ref_26","unstructured":"Health Products Regulatory Authority (Ireland) (2025, December 01). Adaluzis 500mg, Powder for Concentrate for Solution for Infusion. Summary of Product Characteristics (Date of Revision of the Text: February 2025). Available online: https:\/\/assets.hpra.ie\/products\/Human\/30880\/Licence_PA23450-003-001_07022025123450.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/bs.podrm.2020.07.005","article-title":"Validation of in-vitro bioassay methods: Application in herbal drug research","volume":"46","year":"2021","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"118881","DOI":"10.1016\/j.ijpharm.2019.118881","article-title":"Supramolecular amphiphiles of Beta-cyclodextrin and Oleylamine for enhancement of vancomycin delivery","volume":"574","author":"Salih","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_29","first-page":"3173","article-title":"Cyclodextrin-erythromycin complexes as a drug delivery device for orthopedic application","volume":"6","author":"Song","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kone\u010dn\u00e1, K., Diepoltov\u00e1, A., Holmanov\u00e1, P., Jand\u2019ourek, O., Vejsov\u00e1, M., Voxov\u00e1, B., B\u00e1rta, P., Maixnerov\u00e1, J., Trejtnar, F., and Ku\u010derov\u00e1-Chlup\u00e1\u010dov\u00e1, M. (2022). Comprehensive insight into anti-staphylococcal and anti-enterococcal action of brominated and chlorinated pyrazine-based chalcones. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.912467"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jit\u0103reanu, A., Agoroaei, L., Caba, I.-C., Cojocaru, F.-D., Vere\u0219tiuc, L., Vieriu, M., and M\u00e2r\u021bu, I. (2025). The Evolution of In Vitro Toxicity Assessment Methods for Oral Cavity Tissues\u2014From 2D Cell Cultures to Organ-on-a-Chip. Toxics, 13.","DOI":"10.3390\/toxics13030195"},{"key":"ref_32","unstructured":"Clinical & Laboratory Standards Institute (2024). Performance Standards for Antimicrobial Susceptibility Testing, Clinical & Laboratory Standards Institute. [34th ed.]. CLSI Supplement M100."},{"key":"ref_33","unstructured":"Iverson, D. (2021). OpenVnmrJ, Zenodo. Version 3.1."},{"key":"ref_34","unstructured":"Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Petersson, G.A., and Nakatsuji, H. (2009). Gaussian 09, Revision A.01, Gaussian, Inc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11623","DOI":"10.1021\/j100096a001","article-title":"Ab Initio Calculation of Vibrational Absorption and Circular Dichroism Spectra Using Density Functional Force Fields","volume":"98","author":"Stephens","year":"1994","journal-title":"J. Phys. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00533485","article-title":"The influence of polarization functions on molecular orbital hydrogenation energies","volume":"28","author":"Hariharan","year":"1973","journal-title":"Theor. Chim. Acta"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1063\/1.438955","article-title":"Self-consistent molecular orbital methods. XX. A basis set for correlated wave functions","volume":"72","author":"Raghavachari","year":"1980","journal-title":"J. Chem. Phys."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0009-2614(98)00106-7","article-title":"Ab initio study of ionic solutions by a polarizable continuum dielectric model","volume":"286","author":"Cossi","year":"1998","journal-title":"Chem. Phys. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1063\/1.471789","article-title":"A comparison of models for calculating nuclear magnetic resonance shielding tensors","volume":"104","author":"Cheeseman","year":"1996","journal-title":"J. Chem. Phys."},{"key":"ref_40","unstructured":"(2023, October 18). PubChem. Ceftobiprole, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ceftobiprole."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-2946-4-17","article-title":"Avogadro: An advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"Hanwell","year":"2012","journal-title":"J. Cheminf."},{"key":"ref_42","unstructured":"Case, D.A., Belfon, K., Ben-Shalom, I.Y., Brozell, S.R., Cerutti, D.S., Cheatham, T.E., Cruzeiro, V.W.D., Darden, T.A., Duke, R.E., and Giambasu, G. (2020). AMBER 2020, University of California."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jmgm.2005.12.005","article-title":"Automatic atom type and bond type perception in molecular mechanical calculations","volume":"25","author":"Wang","year":"2006","journal-title":"J. Mol. Graph. Model."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sousa da Silva, A.W., and Vranken, W.F. (2012). ACPYPE\u2014AnteChamber PYthon Parser interfacE. BMC Res. Notes, 5.","DOI":"10.1186\/1756-0500-5-367"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"ref_47","first-page":"5068","article-title":"From Proteins to Perturbed Hamiltonians: A Suite of Tutorials for the GROMACS-2018 Molecular Simulation Package [Article v1.0]","volume":"1","author":"Lemkul","year":"2018","journal-title":"Living J. Comput. Mol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/jcc.21787","article-title":"MDAnalysis: A toolkit for the analysis of molecular dynamics simulations","volume":"32","author":"Denning","year":"2011","journal-title":"J. Comput. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Gowers, R.J., Linke, M., Barnoud, J., Reddy, T.J.E., Melo, M.N., Seyler, S.L., Doma\u0144ski, J., Dotson, D.L., Buchoux, S., and Kenney, I.M. (2016, January 11\u201317). MDAnalysis: A Python Package for the Rapid Analysis of Molecular Dynamics Simulations. Proceedings of the 15th Python in Science Conference, Austin, TX, USA.","DOI":"10.25080\/Majora-629e541a-00e"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array programming with NumPy","volume":"585","author":"Harris","year":"2020","journal-title":"Nature"},{"key":"ref_51","unstructured":"Clinical & Laboratory Standards Institute (2012). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved Standard, CLSI Guideline M07-A9, Clinical & Laboratory Standards Institute. [9th ed.]."},{"key":"ref_52","unstructured":"Clinical & Laboratory Standards Institute (1999). Methods for Determining Bactericidal Activity of Antimicrobial Agents, CLSI Guideline M26-A, Clinical & Laboratory Standards Institute."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12108\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:41:31Z","timestamp":1765899691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":52,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262412108"],"URL":"https:\/\/doi.org\/10.3390\/ijms262412108","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}